Studies Conducted at Department of Radiation Oncology on Prostate Cancer Recently Published (Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience).

A recent study conducted at the Department of Radiation Oncology in Dijon, France, examined the use of carboplatin and etoposide chemotherapy in the treatment of metastatic prostate cancer (mPC). The study analyzed the efficacy and tolerance of this chemotherapy in three different groups of mPC patients: those with primary small-cell neuroendocrine (PSC-NE) carcinoma, adenocarcinoma with neuroendocrine (NE) marker elevation, and adenocarcinoma without NE marker elevation. The results showed that the benefit/risk ratio of this chemotherapy was unfavorable in heavily pretreated adenocarcinoma patients due to poor response and high toxicity. The study suggests that PSC-NE and castration-resistant adenocarcinoma of the prostate should not be mixed. [Extracted from the article]